Mitsubishi Tanabe completes Choseido acquisition
This article was originally published in Scrip
Mitsubishi Tanabe Pharmaceutical(MTP) has completed its acquisition of the small Japanese generics firm Choseido Pharmaceutical. MTP raised its ownership of the firm from 10% to 51% through the purchase of 697,000 shares, in a deal first announced earlier this year (Scrip Online, May 8th, 2008). The price was not disclosed but MTP said the impact on its results would be minor. Choseido had sales of ¥5.6 billion ($51.4 million) in the last fiscal year, and will manufacture products for sale through MTP's new generics marketing operation, Tanabe Seiyaku Hanbai.
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?